On the other hand, the selective ETBR antagonist BQ-788 did not show any effects of improving the clinical changes of IMQ-induced psoriasiform dermatitis (Supplemental Fig. S1). This evidence concerns the gene EDNRB and Psoriasiform dermatitis.